Merck to Acquire Verona Pharma for ~$10B

Shots:

• Merck has entered into a definitive agreement to acquire Verona Pharma incl. its asset Ohtuvayre (ensifentrine), expanding its cardio-pulmonary pipeline & portfolio
• As per the deal, Merck will acquire Verona Pharma for $107 per American Depository Share (ADS), each representing 8 ordinary Verona shares, for an aggregate of ~$10B; closing expected in Q4’25
• Ohtuvayre (PDE3 & PDE4 dual inhibitor) was approved by the US FDA as the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults & is being evaluated to treat non-cystic fibrosis bronchiectasis

Ref: Merck | Image: Verona Pharma| Press Release

Related News:- Merck Reports the Data from P-III (HYPERION) Study of WINREVAIR (sotatercept-csrk) in Adults with Recently Diagnosed PAH

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com